Journal article 98 views 13 downloads
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
Deborah B Horn,
Donna H Ryan,
Sanja Giljanovic Kis,
Breno Alves,
Yiming Mu,
Sin Gon Kim,
Jens Aberle,
Steve Bain 
,
Sheryl Allen,
Elizabeth Sarker,
Qiwei Wu,
Adam Stefanski,
Irina Jouravskaya
,
Sheryl Allen,
Elizabeth Sarker,
Qiwei Wu,
Adam Stefanski,
Irina Jouravskaya
The Lancet
Swansea University Author:
Steve Bain
-
PDF | Accepted Manuscript
Author accepted manuscript document released under the terms of a Creative Commons CC-BY licence using the Swansea University Research Publications Policy (rights retention).
Download (232.99KB)
DOI (Published version): 10.1016/s0140-6736(25)02165-8
Abstract
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
| Published in: | The Lancet |
|---|---|
| ISSN: | 0140-6736 1474-547X |
| Published: |
Elsevier BV
2025
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa71022 |
| College: |
Faculty of Medicine, Health and Life Sciences |
|---|---|
| Funders: |
This study was funded by Eli Lilly and Company. |